Z 004
Alternative Names: Z-004Latest Information Update: 29 Apr 2024
At a glance
- Originator Ziphius Vaccines
- Class Antifibrotics; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 17 Apr 2024 Z 004 is available for licensing as of 17 Apr 2024. https://ziphius.org/pipeline (Ziphius Vaccines pipeline, April 2024)
- 17 Apr 2024 Preclinical trials in Cystic fibrosis in Belgium (Parenteral) prior to April 2024 (Ziphius Vaccines pipeline, April 2024)